Cystic Fibrosis Diagnostics Market: By Test Type, Newborn screening, Prenatal Screening), By Product Type, By End User and Geography

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Cystic Fibrosis (CF) Diagnostics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Test Type (Antenatal Testing, Carrier Testing, Sweat Tests, CFTR-Related Metabolic Syndrome (CRMS), Newborn screening, Prenatal Screening), By Product Type (Diagnostic Kits, Reagents, and Others), By End User (Hospitals and Diagnostic Centers) and Region

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Cystic fibrosis (CF) diagnostics market size was valued at US$ 8.13 billion in 2023, growing at a CAGR of 18% from 2024-30. Cystic fibrosis (CF) is a chronic, genetic disease that causes persistent lung infections and limits the ability to breathe over time. Several mutations in the gene is responsible for Cystic fibrosis that encodes cystic fibrosis transmembrane conductance regulator (CFTR) protein. Patients with CF have inherited two copies of the defective CF gene one copy from each parent.

Both parents must have at least one copy of the defective gene. Currently, there are approximately 70,000 people who are suffering from cystic fibrosis worldwide, according to the Cystic Fibrosis Foundation (CFF). Some of the popular methods of diagnosis are antenatal testing, carrier testing, and other tests such as genetic tests and sweat tests According to Cystic Fibrosis Foundation, the incidence of these hereditary disorders is constantly growing. Nonprofit organizations are investing huge amounts of funds to find various therapeutics for CF and to support research & developmental activities. 

Cystic Fibrosis (CF) Diagnostics Market Key Developments

  • In February 2018, Luminex's xTAG Cystic Fibrosis 71 Kit v2 was approved for sale with LICENSALE.COM in Brazil. In March 2017, Elucigene Diagnostics announced the official launch of a new CF-Italia kit (CF1ITB1). In April 2017, Elucigene Diagnostics partnered with Southern Cross Diagnostics in order to expand in Australia and New Zealand markets.

summary download arrow Download Free Sample

Cystic Fibrosis Cf Diagnostics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

18%

Largest Market

North America

Fastest Growing Market

Europe

Cystic Fibrosis (CF) Diagnostics Market Dynamics

The major driver for the market is improved diagnostic technologies. Increase in investment and awareness about genetic diseases are aiding in development of diagnostic technologies, which will fuel the market growth. The high cost of the drugs and treatment may hamper the growth of the market. The global cystic fibrosis diagnostics market is expected to witness tremendous growth. Novel diagnostic tools for cystic fibrosis are being developed.

The scientists at Stanford University, have developed a DNA test for the accurate and comprehensive screening of newborns for cystic fibrosis. By this test the next-generation DNA sequencing can be identified and this test is considered to be less expensive and less time-consuming technology.

Cystic Fibrosis Cf Diagnostics Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 8.13 billion

Market CAGR

18%

By Test Type

  • Antenatal Testing
  • Carrier Testing
  • Sweat Tests
  • CFTR-Related Metabolic Syndrome (CRMS)
  • Newborn Screening
  • Prenatal Screening

By Product Type

  • Diagnostic Kits
  • Reagents
  • Others

By End User

  • Hospital
  • Diagnostic centers

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa.

Key Features of the Report

  • The cystic fibrosis cf diagnostics market provides granular level information about the market size, regional market share, historic market (2019 to 2023) and forecast (2024 to 2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The global cystic fibrosis cf diagnostics market size was valued at US$ 8.13 billion in 2023 and is projected to grow at a CAGR of 18% from 2024 to 2030.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

The cystic fibrosis (CF) diagnostics market key players are: Elucigene, Asper Biogene, ELITechGroup, Natera, Inc., Randox Laboratories Ltd., Luminex Corporation, Appolon Bioteck, Arazy Group, Illumina Inc.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Cystic Fibrosis Cf Diagnostics Market Introduction 
2.1.Global Cystic Fibrosis Cf Diagnostics Market  - Taxonomy
2.2.Global Cystic Fibrosis Cf Diagnostics Market  - Definitions
2.2.1.Test Type
2.2.2.Product Type
2.2.3.End User
2.2.4.Region
3.Global Cystic Fibrosis Cf Diagnostics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Cystic Fibrosis Cf Diagnostics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Cystic Fibrosis Cf Diagnostics Market  By Test Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Antenatal Testing
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Carrier Testing
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Sweat Tests
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. CFTR-Related Metabolic Syndrome (CRMS)
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Newborn Screening
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Prenatal Screening
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
6.Global Cystic Fibrosis Cf Diagnostics Market  By Product Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Diagnostic Kits
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Reagents
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Others
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7.Global Cystic Fibrosis Cf Diagnostics Market  By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Hospital
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Diagnostic centers
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
8.Global Cystic Fibrosis Cf Diagnostics Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Cystic Fibrosis Cf Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Test Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Antenatal Testing
9.1.2.Carrier Testing
9.1.3.Sweat Tests
9.1.4.CFTR-Related Metabolic Syndrome (CRMS)
9.1.5.Newborn Screening
9.1.6.Prenatal Screening
9.2.  Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Diagnostic Kits
9.2.2.Reagents
9.2.3.Others
9.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital
9.3.2.Diagnostic centers
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Cystic Fibrosis Cf Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Test Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Antenatal Testing
10.1.2.Carrier Testing
10.1.3.Sweat Tests
10.1.4.CFTR-Related Metabolic Syndrome (CRMS)
10.1.5.Newborn Screening
10.1.6.Prenatal Screening
10.2.  Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Diagnostic Kits
10.2.2.Reagents
10.2.3.Others
10.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital
10.3.2.Diagnostic centers
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Cystic Fibrosis Cf Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Test Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Antenatal Testing
11.1.2.Carrier Testing
11.1.3.Sweat Tests
11.1.4.CFTR-Related Metabolic Syndrome (CRMS)
11.1.5.Newborn Screening
11.1.6.Prenatal Screening
11.2.  Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Diagnostic Kits
11.2.2.Reagents
11.2.3.Others
11.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital
11.3.2.Diagnostic centers
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Cystic Fibrosis Cf Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Test Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Antenatal Testing
12.1.2.Carrier Testing
12.1.3.Sweat Tests
12.1.4.CFTR-Related Metabolic Syndrome (CRMS)
12.1.5.Newborn Screening
12.1.6.Prenatal Screening
12.2.  Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Diagnostic Kits
12.2.2.Reagents
12.2.3.Others
12.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital
12.3.2.Diagnostic centers
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Cystic Fibrosis Cf Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Test Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Antenatal Testing
13.1.2.Carrier Testing
13.1.3.Sweat Tests
13.1.4.CFTR-Related Metabolic Syndrome (CRMS)
13.1.5.Newborn Screening
13.1.6.Prenatal Screening
13.2.  Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Diagnostic Kits
13.2.2.Reagents
13.2.3.Others
13.3.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital
13.3.2.Diagnostic centers
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Elucigene
14.2.2.Asper Biogene
14.2.3.ELITechGroup
14.2.4.Natera, Inc.
14.2.5.Randox Laboratories Ltd.
14.2.6.Luminex Corporation
14.2.7.Appolon Bioteck
14.2.8.Arazy Group
14.2.9.Illumina Inc.
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • Elucigene
  • Asper Biogene
  • ELITechGroup
  • Natera, Inc.
  • Randox Laboratories Ltd.
  • Luminex Corporation
  • Appolon Bioteck
  • Arazy Group
  • Illumina Inc.

Related Industry Reports

Idiopathic Pulmonary Fibrosis Market

Cystic Fibrosis Market

Cystic Fibrosis Pipeline Drugs Assessment

Idiopathic Pulmonary Fibrosis Disease Pipeline Drugs Assessment